N
RCKT icon

Natixis’s Rocket Pharmaceuticals RCKT Stock Holding History

Natixis’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-48,400
Closed -$608K – 1157
2024
Q4 		$608K Buy
+48,400
New +$729K ﹤0.01% 673
2024
Q1 		– Sell
-649
Closed -$19.5K – 1193
2023
Q4 		$19.5K Hold
649
– – ﹤0.01% 880
2023
Q3 		$13.3K Sell
649
-11
-2% -$200 ﹤0.01% 883
2023
Q2 		$13.1K Sell
660
-34
-5% -$687 ﹤0.01% 922
2023
Q1 		$11.9K Hold
694
– – ﹤0.01% 888
2022
Q4 		$13.6K Buy
+694
New +$12.8K ﹤0.01% 989
2022
Q1 		– Sell
-225,394
Closed -$4.92M – 1296
2021
Q4 		$4.92M Buy
+225,394
New +$6.15M 0.02% 555

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Natixis's RCKT Position: Q1 2025 in Review

Natixis sold out of Rocket Pharmaceuticals (RCKT) in Q1 2025, closing a stake of 48,400 shares — an estimated $608K sold.

Natixis first reported a position in RCKT in Q4 2021 and held it in 7 quarters. The position peaked at $4.92M in Q4 2021. 236 funds tracked by Wall St. Rank hold RCKT as of Q1 2025.

  • Natixis reported no remaining Rocket Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Natixis sold 48,400 Rocket Pharmaceuticals shares in Q1 2025, an estimated $608K.
  • Natixis first reported a position in Rocket Pharmaceuticals in Q4 2021 and held it in 7 quarters.
  • Natixis's Rocket Pharmaceuticals position peaked at $4.92M in Q4 2021.
  • 236 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2025.

Based on Natixis's 13F filing for Q1 2025, filed 14 May 2025.